Effective immunotherapy options for patients with non-small cell lung
cancer (NSCLC) are becoming increasingly available. The immunotherapy focus has
been on tumor infiltrating T cells (TILs); however, tumor infiltrating B cells
(TIL-Bs) have also been reported to correlate with NSCLC patient survival. The
function of TIL-Bs in human cancer has been understudied, with little focus on
their role as antigen-presenting cells and their influence on
CD4+ TILs. Compared to other immune subsets detected in
freshly isolated primary tumors from NSCLC patients, we observed increased
numbers of intratumoral B cells relative to B cells from tumor-adjacent tissues.
Furthermore, we demonstrated that TIL-Bs can efficiently present antigen to
CD4+ TILs and alter the CD4+ TIL
phenotype using an in vitro antigen-presentation assay.
Specifically, we identified three CD4+ TIL responses to
TIL-Bs, which we categorized as: activated, antigen-associated, and
non-responsive. Within the activated and antigen-associated
CD4+ TIL population, activated TIL-Bs
(CD19+CD20+CD69+CD27+CD21+)
were associated with an effector T-cell response
(IFNγ+ CD4+ TILs).
Alternatively, exhausted TIL-Bs
(CD19+CD20+CD69+CD27–CD21–)
were associated with a regulatory T-cell phenotype (FoxP3+
CD4+ TILs). Our results demonstrate a new role for TIL-Bs
in NSCLC tumors in their interplay with CD4+ TILs in the
tumor microenvironment, establishing them as a potential therapeutic target in
NSCLC immunotherapy.